Literature DB >> 25413704

Adding value to antiretroviral proficiency testing.

Robin DiFrancesco1, Charlene R Taylor, Susan L Rosenkranz, Kelly M Tooley, Poonam G Pande, Suzanne M Siminski, Richard W Jenny, Gene D Morse.   

Abstract

BACKGROUND: Clinical trial specimens tested for antiretroviral (ARV) concentrations often require compliance with Clinical Laboratory Improvement Act and/or the Food and Drug Administration bioanalytical guidance. EXPERIMENTAL: The Clinical Pharmacology Quality Assurance Program (CPQA) designed 8 proficiency testing (PT) rounds over 4 years to assess precision, specificity and stability.
RESULTS: Ten laboratories provided blinded proficiency data to support continued acceptable precision of ARV methods. Specificity samples identified little bias for individual methods; hemolyzed (87%) and lipemic (86%) results were ≤ 10% of their control results. Stability was established for ARVs in plasma at -70°C for 2.5-3.6 years.
CONCLUSION: PT provided by the CPQA assured continued acceptability of individual laboratory assay performances for precision and specificity, and obtained ARV stability during long term storage.

Entities:  

Mesh:

Year:  2014        PMID: 25413704      PMCID: PMC4296581          DOI: 10.4155/bio.14.139

Source DB:  PubMed          Journal:  Bioanalysis        ISSN: 1757-6180            Impact factor:   2.681


  15 in total

1.  Adding value to proficiency testing programs.

Authors:  G S Cembrowski; R N Carey
Journal:  Clin Chem       Date:  2000-01       Impact factor: 8.327

2.  Medicare, Medicaid and CLIA programs; regulations implementing the Clinical Laboratory Improvement Amendments of 1988 (CLIA)--HCFA. Final rule with comment period.

Authors: 
Journal:  Fed Regist       Date:  1992-02-28

3.  Evaluation of antiretroviral drug measurements by an interlaboratory quality control program.

Authors:  Jacqueline A H Droste; Rob E Aarnoutse; Peter P Koopmans; Yechiel A Hekster; David M Burger
Journal:  J Acquir Immune Defic Syndr       Date:  2003-03-01       Impact factor: 3.731

4.  Quality assurance program for clinical measurement of antiretrovirals: AIDS clinical trials group proficiency testing program for pediatric and adult pharmacology laboratories.

Authors:  Diane T Holland; Robin DiFrancesco; Judith Stone; Fayez Hamzeh; James D Connor; Gene D Morse
Journal:  Antimicrob Agents Chemother       Date:  2004-03       Impact factor: 5.191

5.  Quality assurance program for pharmacokinetic assay of antiretrovirals: ACTG proficiency testing for pediatric and adult pharmacology support laboratories, 2003 to 2004: a requirement for therapeutic drug monitoring.

Authors:  Diane T Holland; Robin DiFrancesco; James D Connor; Gene D Morse
Journal:  Ther Drug Monit       Date:  2006-06       Impact factor: 3.681

6.  Assessing the matrix effects of hemolyzed samples in bioanalysis.

Authors:  Nicola C Hughes; Navgeet Bajaj; Juan Fan; Ernest Y K Wong
Journal:  Bioanalysis       Date:  2009-09       Impact factor: 2.681

7.  The International Interlaboratory Quality Control Program for Measurement of Antiretroviral Drugs in Plasma: a global proficiency testing program.

Authors:  David Burger; Marga Teulen; Jaco Eerland; Anneke Harteveld; Rob Aarnoutse; Daan Touw
Journal:  Ther Drug Monit       Date:  2011-04       Impact factor: 3.681

8.  A study of matrix effects on an LC/MS/MS assay for olanzapine and desmethyl olanzapine.

Authors:  C Chin; Z P Zhang; H T Karnes
Journal:  J Pharm Biomed Anal       Date:  2004-09-03       Impact factor: 3.935

9.  Interference testing.

Authors:  Goce Dimeski
Journal:  Clin Biochem Rev       Date:  2008-08

10.  Major pitfalls in the measurement of artemisinin derivatives in plasma in clinical studies.

Authors:  N Lindegardh; W Hanpithakpong; B Kamanikom; P Singhasivanon; D Socheat; P Yi; A M Dondorp; R McGready; F Nosten; N J White; N P J Day
Journal:  J Chromatogr B Analyt Technol Biomed Life Sci       Date:  2008-10-18       Impact factor: 3.205

View more
  11 in total

1.  Similar tenofovir hair concentrations in men and women after directly observed dosing of tenofovir disoproxil fumarate/emtricitabine: implications for preexposure prophylaxis adherence monitoring.

Authors:  Catherine A Koss; Albert Y Liu; Jose Castillo-Mancilla; Peter Bacchetti; Cricket McHugh; Karen Kuncze; Mary Morrow; Alexander Louie; Sharon Seifert; Hideaki Okochi; Samantha MaWhinney; Monica Gandhi; Peter L Anderson
Journal:  AIDS       Date:  2018-09-24       Impact factor: 4.177

2.  Relationship Dynamics are Associated with Self-Reported Adherence but not an Objective Adherence Measure in Malawi.

Authors:  Amy A Conroy; Stacey McKenna; Allison Ruark; Torsten B Neilands; Matthew Spinelli; Monica Gandhi
Journal:  AIDS Behav       Date:  2022-05-04

3.  Evaluation of a Multidrug Assay for Monitoring Adherence to a Regimen for HIV Preexposure Prophylaxis in a Clinical Study, HIV Prevention Trials Network 073.

Authors:  Yinfeng Zhang; William Clarke; Mark A Marzinke; Estelle Piwowar-Manning; Geetha Beauchamp; Autumn Breaud; Craig W Hendrix; Gavin A Cloherty; Lynda Emel; Scott Rose; Lisa Hightow-Weidman; Marc Siegel; Steven Shoptaw; Sheldon D Fields; Darrell Wheeler; Susan H Eshleman
Journal:  Antimicrob Agents Chemother       Date:  2017-06-27       Impact factor: 5.191

4.  Dose Frequency Ranging Pharmacokinetic Study of Tenofovir-Emtricitabine After Directly Observed Dosing in Healthy Volunteers to Establish Adherence Benchmarks (HPTN 066).

Authors:  Craig W Hendrix; Adriana Andrade; Namandjé N Bumpus; Angela D Kashuba; Mark A Marzinke; Ayana Moore; Peter L Anderson; Lane R Bushman; Edward J Fuchs; Ilene Wiggins; Christine Radebaugh; Heather A Prince; Rahul P Bakshi; Ruili Wang; Paul Richardson; Eugenie Shieh; Laura McKinstry; Xin Li; Deborah Donnell; Vanessa Elharrar; Kenneth H Mayer; Kristine B Patterson
Journal:  AIDS Res Hum Retroviruses       Date:  2015-10-15       Impact factor: 2.205

5.  Comparison of Measures of Adherence to Human Immunodeficiency Virus Preexposure Prophylaxis Among Adolescent and Young Men Who Have Sex With Men in the United States.

Authors:  Catherine A Koss; Sybil G Hosek; Peter Bacchetti; Peter L Anderson; Albert Y Liu; Howard Horng; Leslie Z Benet; Karen Kuncze; Alexander Louie; Parya Saberi; Craig M Wilson; Monica Gandhi
Journal:  Clin Infect Dis       Date:  2018-01-06       Impact factor: 9.079

6.  Tenofovir and emtricitabine concentrations in hair are comparable between individuals on tenofovir disoproxil fumarate versus tenofovir alafenamide-based ART.

Authors:  Hideaki Okochi; Alexander Louie; Nhi Phung; Kevin Zhang; Regina M Tallerico; Karen Kuncze; Matthew A Spinelli; Catherine A Koss; Leslie Z Benet; Monica Gandhi
Journal:  Drug Test Anal       Date:  2021-04-13       Impact factor: 3.234

7.  Boceprevir and Antiretroviral Pharmacokinetic Interactions in HIV/HCV Co-infected Persons: AIDS Clinical Trials Group Study A5309s.

Authors:  Jennifer J Kiser; Darlene Lu; Susan L Rosenkranz; Gene D Morse; Robin DiFrancesco; Kenneth E Sherman; Adeel A Butt
Journal:  Drugs R D       Date:  2017-12

Review 8.  Optimizing Pediatric Dosing Recommendations and Treatment Management of Antiretroviral Drugs Using Therapeutic Drug Monitoring Data in Children Living With HIV.

Authors:  Hylke Waalewijn; Anna Turkova; Natella Rakhmanina; Tim R Cressey; Martina Penazzato; Angela Colbers; David M Burger
Journal:  Ther Drug Monit       Date:  2019-08       Impact factor: 3.681

9.  Transgender women on oral HIV pre-exposure prophylaxis have significantly lower tenofovir and emtricitabine concentrations when also taking oestrogen when compared to cisgender men.

Authors:  Eugenie Shieh; Mark A Marzinke; Edward J Fuchs; Allyson Hamlin; Rahul Bakshi; Wutyi Aung; Jennifer Breakey; Tonia Poteat; Todd Brown; Namandjé N Bumpus; Craig W Hendrix
Journal:  J Int AIDS Soc       Date:  2019-11       Impact factor: 5.396

10.  Detectable HIV RNA in late pregnancy associated with low tenofovir hair levels at time of delivery among women living with HIV in the United States.

Authors:  Jillian Pintye; Yanling Huo; Deborah Kacanek; Kevin Zhang; Karen Kuncze; Hideaki Okochi; Monica Gandhi
Journal:  AIDS       Date:  2021-02-02       Impact factor: 4.632

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.